Saxenda for weight loss: what the liraglutide data actually shows

What's this video probably claiming?

Based on the caption and hashtags, @dra.leon.endocrino appears to be walking through Saxenda (liraglutide 3.0 mg) as an FDA- and EMA-approved weight loss medication, noting its approval for adults and adolescents 12 and older with obesity. The creator is also pushing back on the miracle-drug narrative that floods GLP-1 content on TikTok, correctly framing Saxenda as one tool inside a broader treatment plan that includes diet and exercise. This is a relatively responsible framing from an endocrinologist. The hashtag pairing of saxenda and victoza is notable: both are liraglutide, but Victoza is dosed for type 2 diabetes (up to 1.8 mg), while Saxenda is the higher 3.0 mg dose specifically for weight management. That distinction matters clinically and regulatorily, and it's worth watching whether the video keeps them clearly separated.

What does the science actually show?

The SCALE Obesity and Prediabetes trial (Pi-Sunyer et al., 2015, NEJM) is the cornerstone liraglutide weight-loss study. Over 56 weeks, participants on liraglutide 3.0 mg lost an average of 8.4 kg compared to 2.8 kg on placebo. About 63% of the liraglutide group lost at least 5% of body weight versus 27% on placebo. That's real but it's also meaningfully less than what semaglutide 2.4 mg produces: the STEP 1 trial (Wilding et al., 2021, NEJM) showed average weight loss of 14.9% of body weight. For adolescents, the SCALE Kids trial (Kelly et al., 2020, NEJM) showed liraglutide 3.0 mg reduced BMI by 2.3% from baseline versus a 1.6% increase in the placebo group. The pediatric approval adds legitimate value, since semaglutide's adolescent data is more recent and less extensive than liraglutide's at this dose.

Where does the social media noise diverge from clinical reality?

Here's where GLP-1 TikTok content tends to fall apart. Liraglutide requires daily subcutaneous injections, versus once-weekly semaglutide. Adherence data shows that's a real barrier. Dropout rates in the SCALE trials ran around 25-30% over 56 weeks, and discontinuation for GI adverse events (nausea, vomiting, diarrhea) affected roughly 10% of participants. Weight regain after stopping is well-documented: a 2022 study by Rubino et al. in Diabetes, Obesity and Metabolism found participants regained about two-thirds of lost weight within one year of stopping liraglutide. That finding rarely makes it into 60-second clips. Additionally, the cost and access picture is rarely discussed: Saxenda lists above $1,300 per month in the U.S. without insurance, which shapes who actually benefits from content like this. The multidisciplinary message is correct, but the systemic barriers deserve equal airtime.

What should you actually know?

Liraglutide 3.0 mg is a legitimate, well-studied weight management drug. Its approval for adolescents aged 12 and older with a BMI at or above the 95th percentile is backed by randomized controlled data, which is more than most pediatric obesity treatments can claim. But it sits in a competitive and rapidly evolving drug class. Semaglutide 2.4 mg (Wegovy) generally produces greater weight loss with a more convenient weekly injection schedule, and tirzepatide (Zepbound) data suggests even larger effects. Liraglutide still has a role, particularly for patients with specific tolerability profiles or payer constraints. The creator's insistence on multidisciplinary care is clinically sound and backed by long-term outcome data. Lifestyle intervention alone produces modest but real results, and drug therapy without behavioral support produces less durable outcomes. Anyone presenting Saxenda as a standalone solution would be misrepresenting the trial protocols under which it was approved.